Initial clinical trials of adoptive regulatory T-cell (Treg) therapy in solid organ transplantation have proven to be both feasible and well tolerated. With Phase 2 trials underway, efforts have been focused on the optimization of the Treg product.
With science and our knowledge on the biology of these cells constantly advancing, we have been able to refine our search for a Treg population that would be ideally suited for therapeutic application. This idealized population must be readily isolated, allow for in-vitro expansion, demonstrate potent and specific suppressor function, maintain lineage stability and demonstrate a relevant homing profile. With the advent of innovative cell analysis/isolation techniques and genetic modifications, we are able to choose and design Tregs to fulfil these criteria.
By utilizing advances in science and technology, we can optimize Treg therapy in human organ transplantation maximizing their prospects in the arena of transplantation tolerance.
aThe Blizard Institute of Cell and Molecular Science, Queen Mary University of London
bDepartment of Immunoregulation and Immune Intervention, Faculty of Life Sciences & Medicine, King's College London, Guy's Hospital, London, United Kingdom
Correspondence to Giovanna Lombardi, BSc, PhD, Professor of Human Transplant Immunology, Department of Immunoregulation and Immune Intervention, Faculty of Life Sciences & Medicine, King's College London, Guy's Hospital, Great Maze Pond, London SE1 9RT, United Kingdom. Tel: +44 207 1887674; e-mail: firstname.lastname@example.org